Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.

Wasmann, Roeland E; Smit, Cornelis; van Dongen, Eric P H; Wiezer, René M J; Adler-Moore, Jill; de Beer, Yvo M; Burger, David M; Knibbe, Catherijne A J; Brüggemann, Roger J M

Wasmann, Roeland E; Smit, Cornelis; van Dongen, Eric P H; Wiezer, René M J; Adler-Moore, Jill; de Beer, Yvo M; Burger, David M; Knibbe, Catherijne A J; Brüggemann, Roger J M.

Afiliación

Wasmann RE; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nieuwegein, The Netherlands.
Smit C; Center of Expertise in Mycology Radboudumc/Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
van Dongen EPH; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.
Wiezer RMJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Adler-Moore J; Department of Anesthesiology, Intensive Care and Pain Management, St. Antonius Hospital, Nieuwegein, The Netherlands.
de Beer YM; Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
Burger DM; Department of Biological Sciences, California State Polytechnic University, Pomona, California.
Knibbe CAJ; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.
Brüggemann RJM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nieuwegein, The Netherlands.

Clin Infect Dis ; 70(10): 2213-2215, 2020 05 06.

Article en En | MEDLINE | ID: mdl-31588493

RESUMEN

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604.

Asunto(s)

Antifúngicos; Obesidad Mórbida; Anfotericina B; Antifúngicos/uso terapéutico; Humanos; Obesidad Mórbida/complicaciones; Obesidad Mórbida/tratamiento farmacológico; Estudios Prospectivos

Palabras clave

fungal infection; fungal treatment; obese; optimal dosing; population pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Obesidad Mórbida / Antifúngicos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google